Across TCGA pan-cancer cohorts, RPL5P20 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RPL5P20 data layer.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher RPL5P20 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL5P20 expression acts as an unfavorable survival marker, although some lineages such as MESO and PAAD show a favorable association.
DLBC, BLCA, and BRCA are the cancer types where RPL5P20 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.